Icon
+91 94997 68112
Login Register

Tabrecta - (150 and 200 mg ; Tablet)

Capmatinib Novartis
150 and 200 mg ; Tablet
Less Than $1000 mn
None None
Less Than 5
 None
None None
TABRECTA is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.
Yes
Tabrecta Patent 1 Patent 2 Patent 3 Patent 4 Patent 5
******* *******
  1. *** *, **** : * **** ** ** ***** *** ***** ** *** ***.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.   Privacy Policy.   Terms and Conditions.